You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The Manhattan-based lab will scale its capacity to process 20,000 tests per day by November and provide results dedicated to the city.
In Nature this week: MassIVE.quant resource houses mass spectrometry-based proteomic data, influence of Viking genetics on European populations, and more.
The firm is hoping that researcher-generated data will soon be published in peer-reviewed papers, while it weathers the COVID-19 pandemic.
Exome sequencing and case-control analyses on hundreds of stillborn cases led to more than a dozen apparent risk genes and additional loss-of-function intolerant genes.
The point-of-care test is based on technology developed at the Columbia University Fertility Center for preimplantation genetic testing.
A number of diagnostic labs have considered saliva-based SARS-CoV-2 testing but decided against it, while other groups continue to pursue it.
In Science this week: model to predict coral bleaching, and more.
The test is designed to detect the SARS-CoV-2 nucleocapsid gene in nasopharyngeal, oropharyngeal, nasal, and midturbinate nasal swab samples.
Research institutions in the US and Europe will lead the studies, which will explore different aspects of COVID-19 such as host immune response.
Investigators worldwide are sharing data to search for features in the human genome that might contribute to COVID-19 susceptibility or progression.
Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.
A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.
In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.
According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.